Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article Free
space
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Boumpas, D. T.
space
  arrow  Balow, J. E.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

ARTICLE

Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide Therapy

right arrow Dimitrios T. Boumpas; Howard A. Austin; Ellen M. Vaughan; Cheryl H. Yarboro; John H. Klippel; and James E. Balow

1 September 1993 | Volume 119 Issue 5 | Pages 366-369

Objective: To determine the risk for secondary amenorrhea after pulse cyclophosphamide therapy in premenopausal women with systemic lupus erythematosus.

Design: Controlled, retrospective clinical study.

Setting: Government referral-based research hospital.

Patients: Thirty-nine women younger than 40 years treated with pulse cyclophosphamide therapy for active lupus nephritis or neuropsychiatric lupus. Sixteen women who received pulses of intravenous methylprednisolone were controls.

Interventions: Sixteen patients received pulse cyclophosphamide (0.5 to 1.0 g/m2 body surface area) monthly for a total of 7 doses (short-CY), and 23 patients received 15 or more doses (long-CY). Control patients were treated with monthly pulses of methylprednisolone (1.0 g/m2) for a total of nine doses.

Measurements: Rates of amenorrhea were evaluated according to duration of treatment (number of doses) and age at the initiation of pulse therapy.

Results: Two of 16 patients (12%) in the Short-CY group and 9 of 23 (39%) in the long-CY group developed sustained amenorrhea (P = 0.07). Rates of sustained amenorrhea (short- and long-CY) according to age at the start of pulse therapy were: ≤ 25 years, 2/16 (12%); 26 to 30 years, 4/15 (27%); ≥ 31 years, 5/8 (62%) (P = 0.04). The increased risk for sustained amenorrhea in patients treated with long-CY was most evident in patients older than 25 years (short-CY [2/12] compared with long-CY [7/11]; P = 0.03). Three other patients with short-CY had reversal of amenorrhea fewer than 12 months after cessation of therapy. Amenorrhea was not observed in any of the 16 control patients.

Conclusions: Intermittent pulse cyclophosphamide therapy in patients with systemic lupus erythematosus is associated with sustained amenorrhea, which is related to both age and number of doses of cyclophosphamide.

Author and Article Information
space

From the National Institute of Diabetes and Digestive and Kidney Diseases; the Nursing Department, Clinical Center; the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
Request for Reprints: Dimitrios T. Boumpas, MD, National Institutes of Health (NIH), Building 10, Room 3N-112, Bethesda, MD 20892.
Acknowledgments: The authors thank Lisa A. Miller for her help during the preparation of the manuscript.




This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
M. Costa and D. Colia
Treating infertility in autoimmune patients
Rheumatology, June 1, 2008; 47(suppl_3): iii38 - iii41.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
M. Gayed and C. Gordon
Pregnancy and rheumatic diseases
Rheumatology, November 1, 2007; 46(11): 1634 - 1640.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
M. Walsh, M. James, D. Jayne, M. Tonelli, B. J. Manns, and B. R. Hemmelgarn
Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 968 - 975.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
C.A.A. Silva and H.I. Brunner
Review: Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus
Lupus, August 1, 2007; 16(8): 593 - 599.
[Abstract] [PDF]


Home page
LupusHome page
A. Tincani, M. Nuzzo, A. Lojacono, M. Cattalini, and A. Meini
Review: Contraception in adolescents with systemic lupus erythematosus
Lupus, August 1, 2007; 16(8): 600 - 605.
[Abstract] [PDF]


Home page
LupusHome page
C.A.A. Silva, M.O. Hilario, M.V. Febronio, S.K. Oliveira, M.T. Terreri, S.B. Sacchetti, F.R. Sztajnbok, R. Marini, M.V. Quintero, B.E. Bica, et al.
Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study
Lupus, July 1, 2007; 16(7): 531 - 536.
[Abstract] [PDF]


Home page
Rheumatology (Oxford)Home page
G. G. Illei, C. H. Yarboro, T. Kuroiwa, R. Schlimgen, H. A. Austin, J. F. Tisdale, P. Chitkara, T. Fleisher, J. H. Klippel, J. E. Balow, et al.
Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis
Rheumatology, June 1, 2007; 46(6): 952 - 956.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
G. Moroni, B. Gallelli, S. Quaglini, G. Banfi, E. Rivolta, P. Messa, and C. Ponticelli
Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up
Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1541 - 1548.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
H I Brunner, A Bishnoi, A C Barron, L J Houk, A Ware, Y Farhey, A B Mongey, C F Strife, T B Graham, and M H Passo
Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus
Lupus, April 1, 2006; 15(4): 198 - 206.
[Abstract] [PDF]


Home page
JAMAHome page
M. Petri and R. Brodsky
High-Dose Cyclophosphamide and Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus
JAMA, February 1, 2006; 295(5): 559 - 560.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
N. C. T. Kong
Pregnancy of a lupus patient--a challenge to the nephrologist
Nephrol. Dial. Transplant., February 1, 2006; 21(2): 268 - 272.
[Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. Rahman, S. J. Bowman, I. P. Giles, Y. Ioannou, and D. A. Isenberg
Annus mirabilis--a guide to the 6th European Lupus Meeting, 3-5 March 2005
Rheumatology, August 1, 2005; 44(8): 962 - 964.
[Full Text] [PDF]


Home page
Ann Rheum DisHome page
G H Stummvoll, M Aringer, J S Smolen, S Schmaldienst, E Jimenez-Boj, W H Horl, W B Graninger, and K Derfler
IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study
Ann Rheum Dis, July 1, 2005; 64(7): 1015 - 1021.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. M. Fine
Pharmacological Therapy of Lupus Nephritis
JAMA, June 22, 2005; 293(24): 3053 - 3060.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
G Contreras, E Tozman, N. Nahar, and D. Metz
Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide
Lupus, March 1, 2005; 14(3_suppl): s33 - s38.
[Abstract] [PDF]


Home page
Rheumatology (Oxford)Home page
C. Gorman, A. Bhatia, and A. Rahman
This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis
Rheumatology, March 1, 2005; 44(3): 398 - 401.
[Full Text] [PDF]


Home page
LupusHome page
F A Houssiau
Cyclophosphamide in lupus nephritis
Lupus, January 1, 2005; 14(1): 53 - 58.
[Abstract] [PDF]


Home page
LupusHome page
F Perfumo and A Martini
Lupus nephritis in children
Lupus, January 1, 2005; 14(1): 83 - 88.
[Abstract] [PDF]


Home page
LupusHome page
A. Raptopoulou, P. Sidiropoulos, and D. T Boumpas
Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus
Lupus, December 1, 2004; 13(12): 887 - 890.
[PDF]


Home page
J. Am. Soc. Nephrol.Home page
F. A. Houssiau
Management of Lupus Nephritis: An Update
J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2694 - 2704.
[Full Text] [PDF]


Home page
LupusHome page
G E Katsifis and A G Tzioufas
Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide
Lupus, September 1, 2004; 13(9): 673 - 678.
[Abstract] [PDF]


Home page
LupusHome page
M-C Park, Y-B Park, S Y Jung, I H Chung, K H Choi, and S-K Lee
Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy
Lupus, August 1, 2004; 13(8): 569 - 574.
[Abstract] [PDF]


Home page
LupusHome page
D Jayne and A Tyndall
Autologous stem cell transplantation for systemic lupus erythematosus
Lupus, May 1, 2004; 13(5): 359 - 365.
[Abstract] [PDF]


Home page
LupusHome page
M Petri
Cyclophosphamide: new approaches for systemic lupus erythematosus
Lupus, May 1, 2004; 13(5): 366 - 371.
[Abstract] [PDF]


Home page
LupusHome page
P I Sidiropoulos and D T Boumpas
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients
Lupus, May 1, 2004; 13(5): 391 - 397.
[Abstract] [PDF]


Home page
Rheumatology (Oxford)Home page
P. Riley, S. M. Maillard, L. R. Wedderburn, P. Woo, K. J. Murray, and C. A. Pilkington
Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety
Rheumatology, April 1, 2004; 43(4): 491 - 496.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
G. Contreras, V. Pardo, B. Leclercq, O. Lenz, E. Tozman, P. O'Nan, and D. Roth
Sequential Therapies for Proliferative Lupus Nephritis
N. Engl. J. Med., March 4, 2004; 350(10): 971 - 980.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
D. Jayne, J. Passweg, A. Marmont, D. Farge, X. Zhao, R. Arnold, F. Hiepe, I. Lisukov, M. Musso, J. Ou-Yang, et al.
Autologous stem cell transplantation for systemic lupus erythematosus
Lupus, March 1, 2004; 13(3): 168 - 176.
[Abstract] [PDF]


Home page
LupusHome page
M El Hachmi, M Jadoul, C Lefebvre, G Depresseux, and F A Houssiau
Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome
Lupus, September 1, 2003; 12(9): 692 - 696.
[Abstract] [PDF]


Home page
LupusHome page
C C Mok and C S Lau
Lupus in Hong Kong Chinese
Lupus, September 1, 2003; 12(9): 717 - 722.
[Abstract] [PDF]


Home page
Ann Rheum DisHome page
C P Mavragani and H M Moutsopoulos
Lupus nephritis: current issues
Ann Rheum Dis, September 1, 2003; 62(9): 795 - 798.
[Full Text] [PDF]


Home page
Ann Rheum DisHome page
C C Mok, R W S Wong, and K N Lai
Treatment of severe proliferative lupus nephritis: the current state
Ann Rheum Dis, September 1, 2003; 62(9): 799 - 804.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
G. Sanni and M. A Khamashta
Low-dose pulse cyclophosphamide in the treatment of neuropsychiatric lupus
Lupus, January 1, 2003; 12(1): 1 - 2.
[PDF]


Home page
LupusHome page
L Stojanovich, R Stojanovich, V Kostich, and E Dzjolich
Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study)
Lupus, January 1, 2003; 12(1): 3 - 7.
[Abstract] [PDF]


Home page
LupusHome page
C A A Silva, M M Leal, C Leone, V P Simone, A D Takiuti, M I Saito, and M H B Kiss
Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus
Lupus, July 1, 2002; 11(7): 419 - 425.
[Abstract] [PDF]


Home page
Rheumatology (Oxford)Home page
G. E. Katsifis, A. G. Tzioufas, P. G. Vlachoyiannopoulos, M. Voulgarelis, H. M. Moutsopoulos, and J. P. A. Ioannidis
Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus
Rheumatology, July 1, 2002; 41(7): 780 - 786.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
F. A. Houssiau and M. Jadoul
Cytotoxic therapy of lupus nephritis: recent developments
Nephrol. Dial. Transplant., June 1, 2002; 17(6): 955 - 957.
[Full Text] [PDF]


Home page
Mult SclerHome page
H L Weiner and J A Cohen
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
Multiple Sclerosis, April 1, 2002; 8(2): 142 - 154.
[Abstract] [PDF]


Home page
LupusHome page
S G Pasoto, B B Mendonca, and E Bonfa
Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations
Lupus, March 1, 2002; 11(3): 175 - 180.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
G. G. Illei, H. A. Austin III, M. Crane, L. Collins, M. F. Gourley, C. H. Yarboro, E. M. Vaughan, T. Kuroiwa, C. L. Danning, A. D. Steinberg, et al.
Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis
Ann Intern Med, August 21, 2001; 135(4): 248 - 257.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
D. Adu
The evidence base for the treatment of lupus nephritis in the new millennium
Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1536 - 1538.
[Full Text] [PDF]


Home page
Ann Rheum DisHome page
D L. T. Huong, B Wechsler, D Vauthier-Brouzes, H Beaufils, G Lefebvre, and J-C Piette
Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre
Ann Rheum Dis, June 1, 2001; 60(6): 599 - 604.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
M Mosca, R Neri, S Giannessi, A Pasquariello, R Puccini, W Bencivelli, and S Bombardieri
Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis
Lupus, April 1, 2001; 10(4): 253 - 257.
[Abstract] [PDF]


Home page
LupusHome page
K Takada, G G Illei, and D T Boumpas
Cyclophosphamide for the treatment of systemic lupus erythematosus
Lupus, March 1, 2001; 10(3): 154 - 161.
[Abstract] [PDF]


Home page
LupusHome page
D Adu, J Cross, and D R. Jayne
Treatment of systemic lupus erythematosus with mycophenolate mofetil
Lupus, March 1, 2001; 10(3): 203 - 208.
[Abstract] [PDF]


Home page
LupusHome page
M Petri
Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy
Lupus, March 1, 2001; 10(3): 222 - 226.
[Abstract] [PDF]


Home page
Postgrad. Med. J.Home page
C C Mok and R W S Wong
Pregnancy in systemic lupus erythematosus
Postgrad. Med. J., March 1, 2001; 77(905): 157 - 165.
[Abstract] [Full Text]


Home page
Ann Rheum DisHome page
C. Auzary, D. l. T. Huong, B. Wechsler, D. Vauthier-Brouzes, and J.-C. Piette
Pregnancy in patients with Wegener's granulomatosis: report of five cases in three women
Ann Rheum Dis, October 1, 2000; 59(10): 800 - 804.
[Abstract] [Full Text]


Home page
Rheumatology (Oxford)Home page
H. C. Nossent and W. Koldingsnes
Long-term efficacy of azathioprine treatment for proliferative lupus nephritis
Rheumatology, September 1, 2000; 39(9): 969 - 974.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
M Petri
The egg and I: preserving fertility in systemic lupus erythematosus
Lupus, July 1, 2000; 9(6): 399 - 400.
[PDF]


Home page
Rheumatology (Oxford)Home page
D. Jayne
Evidence-based treatment of systemic vasculitis
Rheumatology, June 1, 2000; 39(6): 585 - 595.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
N. M. Janssen and M. S. Genta
The Effects of Immunosuppressive and Anti-inflammatory Medications on Fertility, Pregnancy, and Lactation
Arch Intern Med, March 13, 2000; 160(5): 610 - 619.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
M Corzillius and S-C Bae
Methodological issues of corticosteroid use in SLE clinical trials
Lupus, October 1, 1999; 8(8): 692 - 697.
[Abstract] [PDF]


Home page
Rheumatology (Oxford)Home page
R. M. Laxer
Long-term toxicity of immune suppression in juvenile rheumatic diseases
Rheumatology, August 1, 1999; 38(8): 743 - 746.
[Full Text] [PDF]


Home page
LupusHome page
E. Cretel, P. Cacoub, D. L. Thi Huong, A. Gompel, Z. Amoura, and J.-C. Piette
Massive ovarian haemorrhage complicating oral anticoagulation in the Antiphospholipid Syndrome: a report of three cases
Lupus, July 1, 1999; 8(6): 482 - 485.
[Abstract] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
M. OSTENSEN
Sex Hormones and Pregnancy in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Ann. N.Y. Acad. Sci., June 22, 1999; 876(1): 131 - 144.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. S. CAMERON
Lupus Nephritis
J. Am. Soc. Nephrol., February 1, 1999; 10(2): 413 - 424.
[Full Text]


Home page
LupusHome page
C A Slater, M H Liang, J W McCune, G M Christman, and M R Laufer
Preserving ovarian function in patients receiving cyclophosphamide
Lupus, January 1, 1999; 8(1): 3 - 10.
[PDF]


Home page
Arch DermatolHome page
M. E. Fleischli, R. H. Valek, and A. G. Pandya
Pulse Intravenous Cyclophosphamide Therapy in Pemphigus
Arch Dermatol, January 1, 1999; 135(1): 57 - 61.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
J M Gloor
Lupus nephritis in children
Lupus, November 1, 1998; 7(9): 639 - 643.
[Abstract] [PDF]


Home page
LupusHome page
A Zonana-Nacach, A Camargo-Coronel, P Yanez, M de Lourdes Sanchez, F J Jaimenez-Balderas, J Aceves-Avila, P Martinez-Osuna, J Fuentes, F Medina, and A Fraga
Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration
Lupus, February 1, 1998; 7(2): 119 - 123.
[Abstract] [PDF]


Home page
Ann Rheum DisHome page
I. Martin-Suarez, D. D'Cruz, M. Mansoor, A. P. Fernandes, M. A Khamashta, and G. R V Hughes
Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide
Ann Rheum Dis, August 1, 1997; 56(8): 481 - 487.
[Abstract] [Full Text]


Home page
BMJ